Truvada Contracts

Our Eligibility & Screening Criteria in Truvada Cases

At Atraxia Media, we help your law firm with effective and measurable marketing that achieves caseload goals. We've set in place an intake strategy that helps us assist your team in quickly onboarding clients who have been injured as a result of taking Truvada:

• Pre-screening. Each lead is pre-screened by our in-house intake specialists, who will determine if it meets your criteria.
• Screening each case. We sift through all the leads to find and send only the best ones to your law firm.
• Following up with people who have been qualified by our intake department. We interview the potential Plaintiffs to ensure that they have a strong case.
• Getting signed contracts for your company. Our experts focus on getting vetted contracts, making your job easier and less stressful.
• Obtaining the highest signup rates in the industry. We assist your legal firm in attracting more clients.
• Handling everything in-house with an intake department that is attorney-run. We make certain that no potential Truvada claimants go unnoticed.
• Delivering Truvada leads that are never sold more than once and are only available to your law practice

Patients may be eligible to get into Truvada litigation and get compensation for their injuries if they:

• Were prescribed Truvada
• Suffered bone loss, kidney disease, or lactic acidosis

Atraxia Media is the first step toward better cases for your law firm. You need dependable marketing services as well as signed contracts that meet your requirements. For advertising and marketing, we rely on social media, AdWords, radio, and television. Then, according to your specifications, our in-house contract and intake professionals screen and vet potential Plaintiffs, ensuring that you receive a qualified contract. We only need to know the volume you require, and we'll provide you with superior marketing, contracts, and cases.

Truvada Facts & History

Truvada claims against Gilead Sciences, Inc. are still new, and, accordingly, settlements have not yet been reached. However, potential lawsuits of thousands of people who have suffered from the serious complications of Truvada are still expected. In addition, people who took Gilead's other HIV drugs containing TDF (Viread, Atripla, Complera, Stribild) have also filed lawsuits for compensation. The individual lawsuits were consolidated into multidistrict litigation (MDL) in December 2018, but the MDL was terminated in February 2019.

Gilead Sciences and other drugmakers also face a growing number of HIV drug class-action lawsuits. Each seeks class-action status to pursue damages against the pharmaceutical companies for all individuals or entities that purchased HIV drugs for use in a cART regimen, alleging that the companies engaged in a long-running scheme to control the market.

Truvada is a pill-based drug that prevents HIV cells from multiplying but does not cure HIV-1 infections or AIDS. Instead, the drug's role is to help reduce the risk of getting HIV-1 infections. Gilead's inaugural HIV drug, Viread, received U.S. Food and Drug Administration (FDA) approval in 2001. Gilead bought the rights to TDF - that had been around since the 1980s but was not feasible for AIDS treatment - and modified it to be taken orally in pill form. That is when the drug started getting used to stop HIV from taking hold and prevent it from spreading.

Several studies have linked Truvada and the other TDF-based HIV pills with serious side effects, including bone density loss, lactic acidosis, and kidney problems. These side effects have led to hundreds of Truvada lawsuits against Gilead Sciences, Inc.

TENOFOVIR DISOPROXIL FUMARATE PRODUCTS LIABILITY LITIGATION, NO. 2881 (TERMINATED)

Plaintiff Allegations:

Allegations against Gilead Sciences, Inc include:

• Failing to disclose Truvada's significant risk for toxicity and bone and kidney damage.
• Failing to warn doctors and patients of the kidney and bone risks in all patients. Accordingly, people could not make informed decisions and, potentially, avoid their injuries.
• Misrepresenting the risks and benefits of Truvada to doctors and patients so it could sell these drugs.
• Withholding a safer version of these drugs and forcing victims to continue to experience damaging side effects.

History:

2021:

• April:
• In a complaint that was filed in the U.S. District Court for the Northern District of California, a group of nearly 30 people joined together against Gilead over the side effects of TDF-based HIV drugs. Plaintiffs allege they suffered kidney injuries, bone damage, and other injuries after taking antiviral medications like Truvada, Atripla, and other TDF-based HIV drugs.
• March:
• According to allegations raised in a product liability lawsuit filed in the U.S. District Court for the Northern District of California on behalf of about 30 plaintiffs, Gilead was aware of the toxic side effects of Viread, Truvada, Atripla, Complera, and Stribild. The company knew there were safer alternatives but withheld development and warnings to increase profits.
• A motion filed by Gilead Sciences, Inc. seeking to dismiss a Truvada lawsuit that alleges the company should have used safer active ingredients in its HIV drugs, was rejected by a federal judge, allowing failure to warn claims to move forward.

2020:

• October:
• Gilead Sciences, Inc. allegedly sold inferior, potentially life-threatening HIV drugs, according to allegations raised in a lawsuit filed in the Northern District of California by a group of 10 people. Plaintiffs allege the company knew it had a safer formulation but chose to increase its profit margins at the expense of patients.
• September:
• According to a class-action lawsuit filed in the U.S. District Court for the Northern District of California by investors in the drug manufacturer, Gilead illegally bribed a generic competitor to delay a competing version of the blockbuster HIV drug Truvada.
• August:
• In a joint product liability lawsuit, a dozen former users of Truvada and other TDF drugs allege that side effects of the HIV drugs caused kidney damage, bone fractures, and other injuries.
• July:
• A group of nearly 20 plaintiffs joined together in a lawsuit indicating that each of them suffered kidney damage, bone density loss, and other complications after using various TDF drugs, including Truvada.
• June:
• In a lawsuit filed against Gilead, more than 70 plaintiffs alleged that they suffered bone and kidney injuries due to the side effects of Truvada, Viread, and other combination HIV drugs; a group of 20 different plaintiffs joined together in a lawsuit against Gilead over failure to warn that side effects of HIV drugs may cause users to suffer bone fractures, kidney injuries, and other complications.
• March:
• A class-action lawsuit over Truvada and other Gilead HIV Drugs was allowed, by a federal judge, to proceed.
• A product liability lawsuit was filed against Gilead by nearly 150 individuals in the U.S. District Court for the Northern District of California over allegations that they suffered bone fractures, kidney problems, and other injuries caused by side effects of HIV drugs like Truvada and Atripla.
• January:
• A product liability lawsuit was filed with the U.S. District Court for the Northern District of California by 86 plaintiffs who suffered kidney and bone injuries from side effects of Gilead HIV drugs; according to allegations raised in another lawsuit, four plaintiffs suffered side effects from Gilead HIV drugs, resulting in acute kidney injuries, bone fractures, and dental injuries.
• A class-action lawsuit was filed by a healthcare insurance company alleging Gilead worked with other drug companies to illegally manipulate the HIV drug market through an illegal scheme that withheld safer treatments.

2019:

• February: In a victory over Gilead, a California Superior Court ruled that plaintiffs' claims may proceed to trial.

2018:

• Starting with 2018, hundreds of lawsuits against Gilead have been filed by individual victims.
• The largest global AIDS organization, AIDS Health Foundation (AHF), helped file one class-action lawsuit that represents TDF victims.
• The majority of Truvada cases are in California, but there are a handful of cases in Delaware, Louisiana, and other states.
• December 19, 2018, the lawsuits were consolidated under MDL-2881 filed in the Judicial Panel on Multidistrict Litigation.